JP7373209B2 - がん免疫治療のための組換え単純ヘルペスウイルス - Google Patents

がん免疫治療のための組換え単純ヘルペスウイルス Download PDF

Info

Publication number
JP7373209B2
JP7373209B2 JP2020568472A JP2020568472A JP7373209B2 JP 7373209 B2 JP7373209 B2 JP 7373209B2 JP 2020568472 A JP2020568472 A JP 2020568472A JP 2020568472 A JP2020568472 A JP 2020568472A JP 7373209 B2 JP7373209 B2 JP 7373209B2
Authority
JP
Japan
Prior art keywords
cancer
cells
protein
hsv
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020568472A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019236931A5 (https=
JP2021527072A5 (https=
JP2021527072A (ja
Inventor
ヘ，ビン
リュー，シン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois System
Original Assignee
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Illinois System filed Critical University of Illinois System
Publication of JP2021527072A publication Critical patent/JP2021527072A/ja
Publication of JPWO2019236931A5 publication Critical patent/JPWO2019236931A5/ja
Publication of JP2021527072A5 publication Critical patent/JP2021527072A5/ja
Application granted granted Critical
Publication of JP7373209B2 publication Critical patent/JP7373209B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2020568472A 2018-06-08 2019-06-07 がん免疫治療のための組換え単純ヘルペスウイルス Active JP7373209B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862682202P 2018-06-08 2018-06-08
US62/682,202 2018-06-08
PCT/US2019/035922 WO2019236931A1 (en) 2018-06-08 2019-06-07 Recombinant herpes simplex virus for cancer immunotherapy

Publications (4)

Publication Number Publication Date
JP2021527072A JP2021527072A (ja) 2021-10-11
JPWO2019236931A5 JPWO2019236931A5 (https=) 2022-06-15
JP2021527072A5 JP2021527072A5 (https=) 2022-06-15
JP7373209B2 true JP7373209B2 (ja) 2023-11-02

Family

ID=67070913

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020568472A Active JP7373209B2 (ja) 2018-06-08 2019-06-07 がん免疫治療のための組換え単純ヘルペスウイルス

Country Status (8)

Country Link
US (2) US12329794B2 (https=)
EP (1) EP3801583B1 (https=)
JP (1) JP7373209B2 (https=)
KR (1) KR102906757B1 (https=)
CN (1) CN112243378B (https=)
AU (1) AU2019282755B2 (https=)
CA (1) CA3142073A1 (https=)
WO (1) WO2019236931A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111635913B (zh) * 2020-06-16 2022-03-04 广东东阳光药业有限公司 构建体及其应用
CN113862229A (zh) * 2020-06-30 2021-12-31 东莞市东阳光生物药研发有限公司 一种重组单纯疱疹病毒及其构建方法
CN113943752A (zh) * 2020-07-15 2022-01-18 东莞市东阳光生物药研发有限公司 构建体、敏感性提高的溶瘤病毒及其应用
CN114075574A (zh) * 2020-08-19 2022-02-22 广东东阳光药业有限公司 构建体、溶瘤病毒及其应用
TW202521570A (zh) * 2023-08-25 2025-06-01 大陸商勃林格殷格翰動物保健（中國）有限公司 用於禽類疫苗的新型ｄｅｖ載體

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520044A (ja) 2000-01-21 2003-07-02 バイオヴェックス リミテッド ヘルペスウイルス株

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7264814B2 (en) * 2001-05-09 2007-09-04 M's Science Corporation Composition and method for treating cancer using herpes virus
GB0714578D0 (en) * 2007-07-26 2007-09-05 Crusade Lab Ltd Viruses
ES2861450T3 (es) 2015-07-20 2021-10-06 Virttu Biologics Ltd Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer
US20170319638A1 (en) 2016-05-06 2017-11-09 Virttu Biologics Limited Treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520044A (ja) 2000-01-21 2003-07-02 バイオヴェックス リミテッド ヘルペスウイルス株

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ma, Y., Chen, M., Jin, H., Prabhakar, B. S., Valyi-Nagy, T., & He, B.，:An engineered herpesvirus activates dendritic cells and induces protective immunity.，Scientific Reports，2017年，7(1)，41461

Also Published As

Publication number Publication date
US20250339482A1 (en) 2025-11-06
CN112243378A (zh) 2021-01-19
WO2019236931A1 (en) 2019-12-12
AU2019282755B2 (en) 2025-09-11
CA3142073A1 (en) 2019-12-12
US20210138009A1 (en) 2021-05-13
EP3801583A1 (en) 2021-04-14
AU2019282755A1 (en) 2021-01-28
KR20210022547A (ko) 2021-03-03
US12329794B2 (en) 2025-06-17
KR102906757B1 (ko) 2025-12-31
EP3801583B1 (en) 2025-07-02
CN112243378B (zh) 2024-12-31
JP2021527072A (ja) 2021-10-11

Similar Documents

Publication Publication Date Title
JP7373209B2 (ja) がん免疫治療のための組換え単純ヘルペスウイルス
US12397053B2 (en) Engineered virus
Manservigi et al. HSV recombinant vectors for gene therapy
TWI704226B (zh) 重組溶瘤病毒組合物及其用途
EP1381280B1 (en) Viral vectors and their use in therapeutic methods
US20210322545A1 (en) Smc combination therapy for the treatment of cancer
Scanlan et al. Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers
JP2020511160A (ja) 組み換え単純ヘルペスウイルス及びその使用
JPH10501990A (ja) 複製能力のある単純ヘルペスウイルスは新生細胞の破壊を媒介する
Zhang et al. Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment
KR20120095450A (ko) 단순 헤르페스 바이러스 백신
CA3207359A1 (en) Adjuvant therapy for cancer
US6897057B1 (en) Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
EP1212428B1 (en) Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression
JP2024512053A (ja) 転写及び翻訳の二重調節を受ける腫瘍溶解性単純ヘルペスウイルスベクター
WO2020106566A1 (en) Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use
US20250161384A1 (en) Transcriptional and translational dual regulated oncolytic herpes simplex virus vectors
Zhou et al. oncolytic HSV-1 virus
Froechlich Dissecting the STING-dependent molecular mechanisms in a preclinical model of combined treatment with tumour-targeted Herpes simplex virus and immune checkpoint blockade
Wongthida Understanding, and exploiting, the contribution of the immune system to the therapeutic efficacy of oncolytic virotherapy with vesicular stomatitis virus (VSV)
HK40049907A (en) Engineered virus
Baird Development of a Novel Model for Exploring the Role of Regulatory T-cells in Oncolytic HSV Cancer Therapy
Gaston Potential roles of the immunostimulatory signals IL-15 and mica in oncolytic HSV-1 therapy for malignant glioma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220607

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231005

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231016

R150 Certificate of patent or registration of utility model

Ref document number: 7373209

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150